Vonbaerwolff

We offer a viable solution to the scarcity of fully functional primary human hepatocytes.

Von Baer Wolff is focused on the fabrication of human hepatocytes with one primary goal: To become the premier supplier of iPS-derived human hepatocytes to science and industry.

Our technology is complex but its benefits are easy to measure. Significant cost savings, improved drug safety and effectiveness, and hope for those affected with liver disease. An abundant supply of human hepatocytes empowers researchers to explore new ideas that can positively impact patient outcomes.

We follow three steps to offer this viable solution:

Step 1: Make primary human hepatocytes from stem cells.

Step 2: Modify them using CRISPR/Cas9 gene-editing tools.

Step 3: Mature and multiply them in in vivo incubators.

For the most recent news about vonbaewolff, please visit www.vonbaerwolff.com